Ein Portrait von Ärztin Manuela Albisetti von der Abteilung Hämatologie

Prof. Dr. med.
Manuela
Albisetti Pedroni

Leitende Ärztin
Leiterin Hämophilie
Hämatologie
Schwerpunkte: Pädiatrie, Hämostaseologie
Akademischer Werdegang

2017: Adjunct Professor of the University of Zurich, Switzerland
2008: Venia legendi  für das Gebiet der Pädiatrie, speziell Hämostaseologie, Medizinischen Fakultät der Universität Zürich, Zürich mit dem Titel «Arterial thrombosis in childhood: specific aspects of fibrinolytic system and therapy»
1995: Swiss Boards in Paediatrics (FMH)
1991: Medical Doctor Degree with the dissertation «Symptome, Diagnose and Therapie des Meckel’schen Divertikels», University of Zurich, Switzerland
1989: Physician Degree, University of Zurich, Switzerland

Facharztausbildung

1992-1995: Paediatrics, Haematology, and Paediatric Surgery, University Children’s Hospital, Zurich, Switzerland
1991-1992: Internal Medicine, «Ospedale Malcantonese» Castelrotto, Switzerland
1990-1991: Paediatrics, «Ospedale Civico», Lugano, Switzerland

Weiterbildung

2000-2001: «Research fellow», The Hospital for Sick Children, Paediatric Thrombophilia Program, Division of Haematology/Oncology, University of Toronto, Toronto,  ON,  Canada (Prof. M. Andrew, Supervisor: Dr. Anthony Chan)
1999-2000: «Research fellow», Paediatric Thrombophilia Program, Hamilton Civic Hospitals Research Centre, McMaster University, Hamilton, ON, Canada (Prof. Maureen Andrew, Supervisor: Dr. Anthony Chan)

Tätigkeiten in Expertengremien
  • since 2020: Editorial Board members of peer-reviewed Journal «Children»
  • 2017-2020: Co-Chairman of the Scientific and Standardization Subcommittee (SSC) on Pediatric and Neonatal Thrombosis and Haemostasis of the International Society on Thrombosis and Haemostasis (ISTH)
  • 2014-2020: President of the Swiss Hemophilia Network
  • 2013-2020: Member of Paediatric Expert Working Group for the Pediatric Investigation Plan of the new oral anticoagulant, dabigatran etexilate, approved by EMA
  • 2010-2020: Member of the faculty department «Frau und Kind», University of Zurich
  • 2007-2020: Medical Board of the Swiss Hemophilia Society
  • Since 2019: Vice Chairman of the Hemophilia Certification Committee of the GTH
  • Since 2019: Board member of the GTH (Gesellschaft für Thrombose- und Hämostaseforschung)
  • 2013-2017: Chair of the working group on catheter-related arterial thrombosis from the Scientific and Standardization Committee (SSC) on Perinatal/Pediatric Haemostasis of the International Society on Thrombosis and Haemostasis (ISTH)
  • since 2015: Member of the Steering Committee for the Pediatric Investigation Plan of the new oral anticoagulant, Edoxaban
  • 2006-2015: Critical Incident Monitoring, University Children’s Hospital, Zurich, Switzerland
  • 2012-2015: Member of the Data Monitoring Committee for a pediatric Phase I study on the new oral anticoagulant, rivaroxaban
  • since 2009: Chair of the executive committee of Paediatric Outpatient Clinic, University Children’s Hospital, Zurich, Switzerland
Mitgliedschaften
  • International Society on Thrombosis and Haemostasis (ISTH)
  • Scientific and Standardization Committee (SSC) on Perinatal/Pediatric Haemostasis of the ISTH
  • Swiss Haemophilia Network
  • Gesellschaft für Thrombose und Haemostase Forschung (GTH)
  • Swiss Society of Paediatrics (SGP)
  • Verbindung der Schweizer Ärztinnen und Ärzte (FMH)
  • World Federation of Hemophilia (WFH)
Forschungsschwerpunkte
  • Bleeding and thrombotic disorders in Children
Publikationen